Impact of a division-wide bundle on hospitalacquired Clostridioides difficile cases, antibiotic days of therapy, testing appropriateness, and associated financial costs

Elizabeth Wenqian Wang; Ashlee Weekley; Jennifer McCarty; Hoonmo Koo; Bradley Lembcke; Mayar Al Mohajer

doi:10.4103/ajm.ajm_193_19

Avicenna Journal of Medicine, Table of Contents

CC BY-NC-ND 4.0 · Avicenna J Med 2021; 11(01): 27-32
DOI: 10.4103/ajm.ajm_193_19

Original Article

Impact of a division-wide bundle on hospitalacquired Clostridioides difficile cases, antibiotic days of therapy, testing appropriateness, and associated financial costs

Authors

Elizabeth Wenqian Wang

Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center

Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine
Ashlee Weekley

Department of Infection Prevention & Control, CHI Baylor St. Luke’s Medical Center, Houston, Texas, USA
Jennifer McCarty

Department of Infection Prevention & Control, CHI Baylor St. Luke’s Medical Center, Houston, Texas, USA
Hoonmo Koo

Department of Infection Prevention & Control, CHI Baylor St. Luke’s Medical Center, Houston, Texas, USA
Bradley Lembcke

Department of Infection Prevention & Control, CHI Baylor St. Luke’s Medical Center, Houston, Texas, USA
Mayar Al Mohajer

Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine

Department of Infection Prevention & Control, CHI Baylor St. Luke’s Medical Center, Houston, Texas, USA

Subject Editor:

Abstract

Introduction: Updated international guidelines recommend the use of a two-step algorithm (glutamate dehydrogenase [GDH] or nucleic-acid amplification test [NAAT] plus toxin) rather than NAAT alone for the diagnosis of Clostridioides difficile (formerly Clostridium difficile) infections. The goal of our project was to evaluate the impact of a new bundle on the rate of hospital-acquired C. difficile infections (CDIs), hospital-acquired CDI standardized infection ratio (SIR), antibiotic days of therapy (DOT), and financial cost. Materials and Methods: The new bundle was implemented in April 2018. This bundle was implemented across five hospitals in Catholic Health Initiatives (CHI) Texas Division. The bundle included a switch from NAAT to a two-step process (GDH and toxin). We placed the new test in an order panel which included enteric isolation and required indications for C. difficile testing. We used quarterly data pre- and post-intervention to calculate SIR and DOT. Results: In the pre-intervention period, 15.5% of the total 3513 C. difficile NAAT was positive. In the post-intervention period, 5.7% of a total of 2845 GDH and toxin assays was positive for both GDH and toxin (P < 0.0001). SIR, which adjusts for denominator and change in testing methodology, also dropped from 1.02 to 0.43. The estimated cost associated with positive C. difficile cases dropped from 1,932,150 USD to 1,113,800 USD with an estimated yearly cost saving of 794,150 USD. Compliance with enteric isolation improved from 73.1% to 92.5% (P = 0.008). Conclusion: The new testing bundle led to a marked reduction in hospital-acquired CDI and unnecessary treatment, reduction in C. difficile testing, an increase in compliance with enteric isolation, and significant cost savings.

Keywords

C. difficile - cost - diagnostic stewardship - DOT - testing

Full Text

References

References
1 Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S. et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015; 175: 1792-801
2 Fenner L, Widmer AF, Goy G, Rudin S, Frei R. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008; 46: 328-30
3 Wilkins TD, Lyerly DM. Clostridium difficile testing: After 20 years, still challenging. J Clin Microbiol 2003; 41: 531-4
4 Shanholtzer CJ, Willard KE, Holter JJ, Olson MM, Gerding DN, Peterson LR. Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. Difficile culture and cytotoxin and latex tests. J Clin Microbiol 1992; 30: 1837-40
5 McDonald LC, Gerding DN, Johnson S, Kelly CP. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: e1-48
6 Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM. et al. European society of clinical microbiology and infectious diseases: Update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016; 22: S63-81
7 Schroeder LF, Robilotti E, Peterson LR, Banaei N, Dowdy DW. Economic evaluation of laboratory testing strategies for hospital-associated Clostridium difficile infection. J Clin Microbiol 2014; 52: 489-96
8 Truong CY, Gombar S, Wilson R, Sundararajan G, Tekic N, Holubar M. et al. Real-time electronic tracking of diarrheal episodes and laxative therapy enables verification of clostridium difficile clinical testing criteria and reduction of clostridium difficile infection rates. J Clin Microbiol 2017; 55: 1276-84
9 Yen C, Holtom P, Butler-Wu SM, Wald-Dickler N, Shulman I, Spellberg B. Reducing clostridium difficile colitis rates via cost-saving diagnostic stewardship. Infect Control Hosp Epidemiol 2018; 39: 734-6
10 Bischoff W, Bubnov A, Palavecino E, Beardsley J, Williamson J, Johnson J. et al. The impact of diagnostic stewardship on Clostridium difficile infections. Open Forum Infect Dis 2017; 4: S398
11 Madden GR, German Mesner I, Cox HL, Mathers AJ, Lyman JA, Sifri CD. et al. Reduced clostridium difficile tests and laboratory-identified events with a computerized clinical decision support tool and financial incentive. Infect Control Hosp Epidemiol 2018; 39: 737-40
12 Mizusawa M, Small BA, Hsu YJ, Sharara SL, Advic E, Kauffman C. et al. Prescriber behavior in Clostridioides difficile testing: A 3-hospital diagnostic stewardship intervention. Clin Infect Dis 2019; 69: 2019-21
13 Madden GR, Sifri CD. Reduced Clostridioides difficile tests among solid organ transplant recipients through a diagnostic stewardship bundled intervention. Ann Transplant 2019; 24: 304-11